CymaBay Therapeutics Announces Acceptance of Arhalofenate Phase 2b Gout Study …

CymaBay Therapeutics Announces Acceptance of Arhalofenate Phase 2b Gout Study …

/EIN News/ — NEWARK, Calif., March 28, 2016 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ:CBAY), today announced the online publication of its Phase 2b study of arhalofenate, a novel dual-acting product candidate for the treatment of …

(Visited 4 times, 1 visits today)
7
Like
Save

Comments

Write a comment